Reassessing the interpretation of oxidation-reduction potential in male infertility.


Journal

Reproduction & fertility
ISSN: 2633-8386
Titre abrégé: Reprod Fertil
Pays: England
ID NLM: 101778727

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 23 02 2022
accepted: 18 03 2022
entrez: 6 5 2022
pubmed: 7 5 2022
medline: 7 5 2022
Statut: epublish

Résumé

Male Infertility Oxidative System (MiOXSYS) has been proposed as a rapid and promising technology for the evaluation of sperm oxidative stress. In this case-control study, 134 men with normal sperm parameters (NSP) and 574 men with abnormal sperm parameters (ASP), according to the World Health Organization sperm assessment references values established in 2010, were enrolled. Conventional sperm parameters were evaluated in all patients. Sperm static oxido-reduction potential (sORP) was assessed using the MiOXSYS. Sperm DNA integrity was measured in 604 patients. To ensure that sperm concentration was not a confounding factor in the sORP index ratio, sperm and seminal fluid sORP from 57 randomly selected additional patients were also measured using the MiOXSYS. sORP index (mV/10 The World Health Organization (WHO) has recognized that oxidative stress may have a role in male infertility. Oxidative stress happens when there is an imbalance between the production of molecules containing oxygen and the antioxidants, molecules that neutralize the molecules containing oxygen. The molecules containing oxygen can cause damage to sperm DNA. This damage can be measured using a particular index and this study looked at whether the concentration of the sperm sample might have an impact on results and suggests this should be taken into consideration by clinicians and researchers.

Identifiants

pubmed: 35514536
doi: 10.1530/RAF-21-0005
pii: RAF-21-0005
pmc: PMC9066566
doi:

Substances chimiques

DNA 9007-49-2
Oxygen S88TT14065

Types de publication

Journal Article

Langues

eng

Pagination

67-76

Informations de copyright

© The authors.

Références

Asian J Androl. 2019 Nov-Dec;21(6):565-569
pubmed: 31006711
Asian J Androl. 2020 May-Jun;22(3):317-322
pubmed: 31339113
Chem Biol. 1995 Jul;2(7):437-45
pubmed: 9383446
Biostatistics. 2009 Jan;10(1):94-105
pubmed: 18556677
Lab Anim. 2012 Jul;46(3):245-52
pubmed: 22829707
Urology. 2017 Jun;104:84-89
pubmed: 28214572
Hum Reprod. 2001 Sep;16(9):1912-21
pubmed: 11527898
Mol Reprod Dev. 2017 Oct;84(10):1039-1052
pubmed: 28749007
Hum Reprod. 2003 May;18(5):1023-8
pubmed: 12721180
Fertil Steril. 2016 Sep 1;106(3):566-573.e10
pubmed: 27260688
Andrologia. 2017 Dec;49(10):
pubmed: 28251671
Genes (Basel). 2019 Mar 19;10(3):
pubmed: 30893955
Int J Androl. 1997 Apr;20(2):61-9
pubmed: 9292315
Oncotarget. 2017 Jan 10;8(2):3600-3627
pubmed: 27690295
Cell Mol Life Sci. 2020 Jan;77(1):93-113
pubmed: 31377843
Arab J Urol. 2018 Feb 01;16(1):87-95
pubmed: 29713539
Int J Reprod Biomed. 2016 Apr;14(4):231-40
pubmed: 27351024
Arab J Urol. 2019 Apr 24;17(2):87-97
pubmed: 31285919
Reprod Biomed Online. 2003 Jul-Aug;7(1):65-70
pubmed: 12930576
Reprod Biomed Online. 2017 Jan;34(1):48-57
pubmed: 27839743
Anim Biotechnol. 2021 Feb;32(1):77-83
pubmed: 31424334
Hum Reprod Update. 2010 May-Jun;16(3):231-45
pubmed: 19934213
Andrologia. 2018 Mar;50(2):
pubmed: 28771782
Reprod Toxicol. 2019 Jun;86:50-55
pubmed: 30905832
Andrologia. 2018 Apr;50(3):
pubmed: 29057493
Andrologia. 2019 Jul;51(6):e13263
pubmed: 30838696
Fertil Steril. 2004 Apr;81(4):965-72
pubmed: 15066449
Reprod Biomed Online. 2014 Jun;28(6):684-703
pubmed: 24745838
Andrologia. 2018 Feb;50(1):
pubmed: 28294377
Nat Rev Urol. 2017 Aug;14(8):470-485
pubmed: 28508879
Urol Clin North Am. 2014 Feb;41(1):169-80
pubmed: 24286775
Front Public Health. 2017 Nov 20;5:307
pubmed: 29209603
Mutat Res Genet Toxicol Environ Mutagen. 2015 Dec;794:75-82
pubmed: 26653986
Fertil Steril. 2000 Mar;73(3):459-64
pubmed: 10688996
Stat Med. 2007 Jul 30;26(17):3258-73
pubmed: 17212380
Oncotarget. 2018 May 11;9(36):24494-24513
pubmed: 29849956
Hum Reprod. 2007 Jan;22(1):174-9
pubmed: 16921163
Fertil Steril. 1975 Jan;26(1):1-5
pubmed: 1109935
Iran Red Crescent Med J. 2013 Sep;15(9):780-5
pubmed: 24616785
Hum Reprod. 2002 Jul;17(7):1856-62
pubmed: 12093852

Auteurs

Fabien Joao (F)

Fertilys Fertility Center, Laval, Quebec, Canada.

Cyntia Duval (C)

Fertilys Fertility Center, Laval, Quebec, Canada.

Marie-Claire Bélanger (MC)

Fertilys Fertility Center, Laval, Quebec, Canada.
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), CHUM Research Center, Montreal, Quebec, Canada.

Julie Lamoureux (J)

Fertilys Fertility Center, Laval, Quebec, Canada.

Cheng Wei Xiao (CW)

Fertilys Fertility Center, Laval, Quebec, Canada.

Senem Ates (S)

Fertilys Fertility Center, Laval, Quebec, Canada.

Moncef Benkhalifa (M)

Fertilys Fertility Center, Laval, Quebec, Canada.
Université Picardie Jules Verne, Médecine et Biologie de la Reproduction et Laboratoire PERITOX, CBH-CHU Amiens Picardie, Amiens, France.

Pierre Miron (P)

Fertilys Fertility Center, Laval, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH